# Erdafitinib in Metastatic Steroid-cell Ovarian Cancer

> **NCT06328491** · NA · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 1 (actual)

## Conditions studied

- Ovarian Cancer
- Steroid Cell Tumor, Malignant

## Interventions

- **DRUG:** Erdafitinib

## Key facts

- **NCT ID:** NCT06328491
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-30
- **Primary completion:** 2022-08-22
- **Final completion:** 2022-08-22
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2024-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06328491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06328491, "Erdafitinib in Metastatic Steroid-cell Ovarian Cancer". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT06328491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*